DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,549,385 | -5.0% | 10,115 | 0.0% | 0.55% | -14.9% |
| Q4 2022 | $2,684,723 | -9.7% | 10,115 | -12.1% | 0.65% | -3.0% |
| Q3 2022 | $2,973,000 | -42.8% | 11,510 | -43.9% | 0.67% | -35.9% |
| Q2 2022 | $5,199,000 | -13.6% | 20,507 | 0.0% | 1.05% | +12.2% |
| Q1 2022 | $6,015,000 | -40.7% | 20,507 | -33.5% | 0.93% | -41.7% |
| Q4 2021 | $10,151,000 | +8.1% | 30,852 | 0.0% | 1.60% | -6.1% |
| Q3 2021 | $9,393,000 | +9.9% | 30,852 | -3.2% | 1.70% | +10.9% |
| Q2 2021 | $8,549,000 | +48.4% | 31,857 | +24.5% | 1.54% | +29.8% |
| Q1 2021 | $5,759,000 | +38.0% | 25,587 | +36.2% | 1.18% | +34.7% |
| Q4 2020 | $4,174,000 | +1369.7% | 18,792 | +1323.6% | 0.88% | +795.9% |
| Q3 2020 | $284,000 | +121.9% | 1,320 | +82.1% | 0.10% | +104.2% |
| Q2 2020 | $128,000 | -86.1% | 725 | -87.9% | 0.05% | -79.2% |
| Q4 2019 | $921,000 | -15.0% | 6,000 | -20.0% | 0.23% | -23.8% |
| Q3 2019 | $1,083,000 | +1.0% | 7,500 | 0.0% | 0.30% | -0.7% |
| Q2 2019 | $1,072,000 | +8.3% | 7,500 | 0.0% | 0.30% | +4.1% |
| Q1 2019 | $990,000 | – | 7,500 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |